| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 08/29/2001 | EP0618925B1 Antisense oligonucleotides |
| 08/29/2001 | CN1310718A Heterocyclic compound as inhibitors of rotamase enzymes |
| 08/29/2001 | CN1310716A Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
| 08/29/2001 | CN1310713A Substituted quinazoline derivatives |
| 08/29/2001 | CN1310708A Substituted phenylamidines with antithrombotic action |
| 08/29/2001 | CN1310707A Novel 2,3,3A,4,9,9A hexahydro-8-hydroxy-1H-benz[f] indoles, a method for the production thereof, and their use as medicaments |
| 08/29/2001 | CN1310706A Inhibitors of phospholipase enzymes |
| 08/29/2001 | CN1310629A Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions |
| 08/29/2001 | CN1310628A Method of raising animals for meat production |
| 08/29/2001 | CN1310626A Hybrid polypeptides with enhanced pharmacokinetic properties |
| 08/29/2001 | CN1310625A Use of alpha1 & beta1 integrin receptor inhibitors and TGF-beta1 inhibitors in the treatment of kidney disease |
| 08/29/2001 | CN1310620A Use of glucose uptake enhancer for reducing apoptosis |
| 08/29/2001 | CN1310619A Use of glucose uptake enhancer for reducing post-ischemic injury of the heart |
| 08/29/2001 | CN1310618A Inhibition of binding of Hox and homeodomain containing proteins and uses thereof |
| 08/29/2001 | CN1310596A Improved methods and apparatus for multi-photon photo-activation of therapeutic agents |
| 08/29/2001 | CN1310585A Process and production for promoting weight loss in overweight dogs |
| 08/29/2001 | CN1310179A Oxamide being as IMPDH inhibitor |
| 08/29/2001 | CN1310021A Health giving and face nursing composition of natural material |
| 08/29/2001 | CN1310013A Medicine for treating cardiovascular damage caused by systematic lupus erythematosus |
| 08/29/2001 | CN1310012A Medicine for treating fever caused by lupus erythematosus and other immunological disease |
| 08/29/2001 | CN1310011A Medicine for treating kidney damage caused by immunological disease lupus erythematosus |
| 08/29/2001 | CN1310010A Medicine for preventing and treating lupus erythematosus and other immunological disease |
| 08/29/2001 | CN1310009A Medicine for treating leucocytopenia caused by lupus erythematosus |
| 08/29/2001 | CN1310008A Lupus erythematosus treating medicine |
| 08/29/2001 | CN1310006A Medicine for treating purpura caused by lupus erythematosus and other immunological disease |
| 08/29/2001 | CN1309997A Hualu health article and its preparation |
| 08/29/2001 | CN1309996A Deer fetus oral liquid and its preparation |
| 08/29/2001 | CN1309970A Application of uridine phosphorylase inhibitor and composition containing the same |
| 08/29/2001 | CN1309965A New pharmaceutical use of sinomenine |
| 08/29/2001 | CN1309964A Carbazole-alkoloid cell cycle inhibitor, cell death inducer and their preparation |
| 08/29/2001 | CN1070193C Process for producing 1-butyl-2-(2'-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl)-1H-indole-3-carboxylic acid |
| 08/29/2001 | CN1070183C Intermediate for producing triterpene derivatives |
| 08/29/2001 | CN1070176C 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceuticals |
| 08/29/2001 | CN1070052C Application of bicycloheptane derivative |
| 08/29/2001 | CA2337661A1 Stabilized granulocyte colony stimulating factor |
| 08/28/2001 | US6281363 Antiinflammatory agents; antiarthritic agents; autoimmune disorders |
| 08/28/2001 | US6281356 Substituted pyrroles |
| 08/28/2001 | US6281354 Analogs of duocarmycin and cc-1065 |
| 08/28/2001 | US6281352 Antiinflammatory agents |
| 08/28/2001 | US6281336 Process for producing immunoglobulins for intravenous administration and other immunoglobulin products |
| 08/28/2001 | US6281243 Derivatives of azetidine and pyrrolidine |
| 08/28/2001 | US6281230 Isoindolines, method of use, and pharmaceutical compositions |
| 08/28/2001 | US6281225 Inhibiting proliferation of arterial smooth muscle cells |
| 08/28/2001 | US6281218 Benzimidazolone derivatives having mixed serotonin and dopamine receptors affinity |
| 08/28/2001 | US6281216 2-aminoquinoline derivatives having d4-agonistic activity |
| 08/28/2001 | US6281206 Amidino and benzamidino compounds |
| 08/28/2001 | US6281205 Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| 08/28/2001 | US6281015 Introducing a microsphere with a bioactive factor to a hepatocyte seeded biodegradable polymer matrix into a transplantation site; enhancing survival and proliferation of transplanted cells |
| 08/28/2001 | US6281000 Dna fragment cloning into genome of recombinant adenoviral plasmid vector; human gene therapy |
| 08/28/2001 | US6280991 Engineered cytotoxic ribonclease |
| 08/28/2001 | US6280975 Adjusted interleukin polypeptide for use in the treatment of myelomas, tumors, osteoporosis and autoimmune diseases |
| 08/28/2001 | US6280971 Polynucleotide associated with detection of staphylococcus; for use in screening bactericides |
| 08/28/2001 | US6280969 Growth arrest homeobox gene |
| 08/28/2001 | US6280959 Zinc chelated cell surface receptor ligands for use as agonist of dimeric cell surface receptors; for example, 2-bis(2,5-bis(2-benzimidazolylimino)-3A,6A-diphenyl-1,2,3,3a, 4,5,6,6a-octahydroimidazo(4,5-d)imidazole-N,N')-zinc(II) |
| 08/28/2001 | US6280957 Preventing graft rejection in humans; administer human a modulator of ligand activity, insert hematopoietic stem cells and graft into human, monitor response to grafts |
| 08/28/2001 | US6280751 For treatment of disease or physical disability or sports injuries, for build up and maintenance of immune system, or for protection against disease or pollution |
| 08/28/2001 | US6280739 Method of inhibiting angiogenesis using secreted proteins |
| 08/28/2001 | US6280732 Administering intracerebrally al-1 immunoadhesin comprising mature al-1 polypeptide having specified amino acid sequence in amount effective to activate autophosphorylation of rek7 |
| 08/28/2001 | CA2178487C Local delivery of fibrinolysis enhancing agents |
| 08/28/2001 | CA2111845C Monoclonal antibodies specific for marrow-derived mesenchymal cells |
| 08/28/2001 | CA2101572C Benzoxazinones as inhibitors of hiv reverse transcriptase |
| 08/28/2001 | CA2015996C Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals |
| 08/25/2001 | CA2337565A1 Use of cladribine on a stent to prevent restenosis |
| 08/24/2001 | CA2337588A1 Oxamides as impdh inhibitors |
| 08/23/2001 | WO2001061055A2 Methods for diagnosing, monitoring, staging, imaging and treating lung cancer via lung cancer specific genes |
| 08/23/2001 | WO2001061039A2 5-hydroxytryptamine transporter gene polymorphisms |
| 08/23/2001 | WO2001061017A2 Modified cytokines for use in cancer therapy |
| 08/23/2001 | WO2001061010A2 Gtpase activating proteins |
| 08/23/2001 | WO2001061009A2 Polypeptides and nucleic acids encoding same |
| 08/23/2001 | WO2001061008A2 Polypeptides and nucleic acids encoding same |
| 08/23/2001 | WO2001060996A1 Method of controlling telomere length |
| 08/23/2001 | WO2001060992A2 Human protein tyrosine phosphatase, encoding dna and uses thereof |
| 08/23/2001 | WO2001060991A2 Human kinases |
| 08/23/2001 | WO2001060983A2 Treatment for bone disorders |
| 08/23/2001 | WO2001060825A1 Pyrrolopyrimidinone derivatives, process of preparation and use |
| 08/23/2001 | WO2001060822A1 Amino acid derivatives and use thereof as nep, ace and ece inhibitors |
| 08/23/2001 | WO2001060821A1 Novel biarylcarboxamides |
| 08/23/2001 | WO2001060819A1 Novel isoxazole and thiazole compounds and use thereof as drugs |
| 08/23/2001 | WO2001060816A1 Kinase inhibitors |
| 08/23/2001 | WO2001060814A2 Pyrrole substituted 2-indolinone protein kinase inhibitors |
| 08/23/2001 | WO2001060813A1 Beta-alanine derivatives and their use as receptor antagonists |
| 08/23/2001 | WO2001060810A1 Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity |
| 08/23/2001 | WO2001060809A1 6-substituted-4,5-epoxy-6-hydroxy-2-cyclohexen-1-one derivatives and intermediates in the production thereof |
| 08/23/2001 | WO2001060808A1 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors |
| 08/23/2001 | WO2001060807A1 Aryloxyacetic acids for diabetes and lipid disorders |
| 08/23/2001 | WO2001060806A2 Substituted arylpyrazines |
| 08/23/2001 | WO2001060805A1 Pyrimidine-4-one derivatives as ldl-pla2 inhibitors |
| 08/23/2001 | WO2001060804A1 Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid |
| 08/23/2001 | WO2001060802A1 4-imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use as alpha-1a agonists |
| 08/23/2001 | WO2001060798A1 Amine derivatives for the treatment of apoptosis |
| 08/23/2001 | WO2001060786A1 Aminoalcohol derivatives |
| 08/23/2001 | WO2001060784A1 Aniline-derived ligands for the thyroid receptor |
| 08/23/2001 | WO2001060417A2 Radioactive therapeutic liposomes |
| 08/23/2001 | WO2001060409A1 Improved paste formulations |
| 08/23/2001 | WO2001060408A2 Microcompetiton and human disease |
| 08/23/2001 | WO2001060407A2 Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis |
| 08/23/2001 | WO2001060405A1 Eosinophil-specific apoptosis inducer |
| 08/23/2001 | WO2001060400A2 Use of inhibitors of caspase-3 or caspase-activated desoxyribonuclease (cad) for treating cardiac disease |
| 08/23/2001 | WO2001060397A1 Uses of agonists and antagonists to modulate activity of tnf-related molecules |
| 08/23/2001 | WO2001060388A1 Cell activator |